NCT00323752View on ClinicalTrials.gov

Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Scoliosis
Interventions
PROCEDURE

rHuEpo

Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.

Trial Locations (1)

Unknown

British Columbia Children's Hospital, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER

NCT00323752 - Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children. | Biotech Hunter | Biotech Hunter